Zevra Therapeutics Quarterly Balance Sheet
NASDAQ: ZVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zevra Therapeutics financial position
As of Jun 30, 2026, Zevra Therapeutics reported total assets of $302.7 million, up 18.1% from a year earlier against total liabilities of $85.1 million. Shareholders' equity stood at $217.7 million, or 71.9% of assets. The company held $145.3 million in cash and equivalents against $0 of debt, a net cash position of $145.3 million.
The current ratio (current assets divided by current liabilities) was 5.17, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.00.
Summary generated from market data by MetaCap's automated system. Methodology
Zevra Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 145.32M | 95.59M | 62.41M | 54.44M | 47.71M | 37.34M | 33.78M | 54.04M | 39.26M | 42.85M | 43.05M | 43.27M |
| Short-Term Investments | 76.25M | 105.02M | 128.60M | 145.07M | 154.90M | 25.29M | 35.71M | 35.34M | 10.00M | 9.87M | 24.69M | 39.67M |
| Receivables | — | — | — | — | — | — | 10.18M | — | — | — | 16.12M | 3.10M |
| Inventory | 2.45M | 2.31M | 1.74M | 1.37M | 1.11M | 2.56M | 1.97M | — | — | — | 0 | — |
| Total Current Assets | 251.30M | 229.97M | 223.01M | 225.12M | 226.34M | 81.57M | 86.03M | 99.44M | 60.89M | 62.89M | 86.94M | 137.01M |
| Property, Plant & Equipment | 641.00K | 430.00K | 489.00K | 488.00K | 599.00K | 422.00K | 356.00K | 607.00K | 678.00K | 695.00K | 736.00K | 642.00K |
| Goodwill | 4.70M | 4.70M | 4.70M | 4.70M | 4.70M | 4.70M | 4.70M | 4.70M | 4.70M | 4.70M | 4.70M | — |
| Intangible Assets | 5.79M | 6.11M | 6.42M | 6.74M | 7.05M | 67.38M | 68.99M | 70.61M | 66.15M | 67.70M | 69.23M | — |
| Long-Term Investments | 38.61M | 36.15M | 47.88M | 30.86M | 15.09M | 6.09M | 6.01M | 6.11M | — | — | 0 | — |
| Total Assets | 302.71M | 278.58M | 284.73M | 270.12M | 256.28M | 172.71M | 178.13M | 191.55M | 144.41M | 151.28M | 172.33M | 138.98M |
| Accounts Payable | 13.96M | 11.69M | 2.48M | 11.07M | 15.84M | 17.82M | 13.07M | 24.46M | 20.45M | 22.79M | 13.99M | 13.08M |
| Total Current Liabilities | 48.63M | 47.03M | 39.28M | 26.11M | 28.83M | 26.98M | 34.06M | 34.48M | 30.45M | 29.91M | 73.72M | 21.71M |
| Long-Term Debt | 0 | 0 | 61.93M | 61.31M | 60.69M | 60.09M | 59.50M | 58.90M | 58.33M | 5.06M | 5.07M | 5.07M |
| Total Liabilities | 85.06M | 72.78M | 130.07M | 136.95M | 139.05M | 131.69M | 138.46M | 121.78M | 111.93M | 102.47M | 110.46M | 71.51M |
| Shareholders' Equity | 217.65M | 205.80M | 154.66M | 133.16M | 117.23M | 41.02M | 39.67M | 69.77M | 32.48M | 48.82M | 61.86M | 61.52M |
| Retained Earnings | -375.42M | -384.17M | -422.06M | -434.23M | -433.68M | -508.39M | -505.29M | -469.55M | -436.32M | -416.40M | -399.78M | -339.47M |
| Total Debt | 0 | 0 | 61.93M | 61.31M | 60.69M | 60.09M | 59.50M | 58.90M | 58.33M | 5.06M | 5.07M | 5.07M |
| Net Cash (Debt) | 221.57M | 200.62M | 129.08M | 138.20M | 141.92M | 2.54M | 9.99M | 30.47M | -9.07M | 47.66M | 62.67M | 77.87M |
| Shares Outstanding | 59.34M | 59.11M | 56.85M | 56.22M | 55.08M | 54.68M | 53.67M | 53.23M | 41.99M | 41.85M | 41.53M | 36.21M |
This table shows 12 quarterly periods of Zevra Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ZVRA's reporting calendar. What is a balance sheet?